Tech Company Financing Transactions
Elephas Biosciences Funding Round
Arch Venture Partners, Northpond Ventures and Sands Capital Management participated in a $40 million Series B funding round for Elephas Biosciences. The financing was announced on 11/6/2025.
Transaction Overview
Company Name
Announced On
11/6/2025
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the launch and commercialization of the proprietary Elephas Live platform as a laboratory developed test (LDT) in 2026.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
918 Deming Way 201
Madison, WI 53717
USA
Madison, WI 53717
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Elephas is solving this problem by developing an imaging platform technology to assess how live tumor fragments respond to cancer therapies. We are removing the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence to accelerate drug development and empower clinical decision making.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maneesh Arora
Chief Financial Officer
Terry Brady
Chief Scientific Officer
Jonathan Oliner
Vice President
Hinco Gierman
VP - Engineering
Pascual Starink
VP - Engineering
Mike Szulczewski
VP - Regulatory Affairs
Ann Leonard
Browse more venture capital transactions:
Prev: 11/6/2025: Giga AI venture capital transaction
Next: 11/6/2025: Inception venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs